Molecular Characteristics of ERCC1-Negative versus ERCC1-Positive Tumors in Resected NSCLC

被引：55

作者：

Friboulet, Luc ^{[1
,2
,7
]}

Barrios-Gonzales, Daniel ^{[2
,3
,7
]}

Commo, Frederic ^{[1
,2
,7
]}

Olaussen, Ken Andre ^{[1
,2
,7
]}

Vagner, Stephan ^{[1
,2
,7
]}

Adam, Julien ^{[1
]}

Goubar, Aicha ^{[1
,2
,7
]}

Dorvault, Nicolas ^{[1
,2
,7
]}

Lazar, Vladimir ^{[5
]}

Job, Bastien ^{[5
]}

Besse, Benjamin ^{[2
,3
,7
]}

Validire, Pierre ^{[6
]}

Girard, Philippe ^{[6
]}

Lacroix, Ludovic ^{[1
,4
]}

Hasmats, Johanna ^{[8
]}

Dufour, Fabienne ^{[3
]}

Andre, Fabrice ^{[1
,2
,3
,7
]}

Soria, Jean-Charles ^{[1
,2
,3
,7
]}

机构：

[1] Inst Gustave Roussy, INSERM, U981, F-94805 Villejuif, France

[2] Inst Cancerol Gustave Roussy IGR, Villejuif, France

[3] IGR, Dept Med, Paris, France

[4] IGR, Lab Rech Translat, Paris, France

[5] IFR54, IGR, Unite Genom Fonct & Bioinformat, Paris, France

[6] Inst Mutualiste Montsouris, Dept Thorac, Paris, France

[7] Univ Paris 11, Le Kremlin Bicetre, France

[8] Royal Inst Technol, Sci Life Lab, Sch Biotechnol, Div Gene Technol, Stockholm, Sweden

来源：

CLINICAL CANCER RESEARCH | 2011年 / 17卷 / 17期

关键词：

CELL LUNG-CANCER; MESSENGER-RNA EXPRESSION; EPIDERMAL-GROWTH-FACTOR; ERCC1; EXPRESSION; DNA-REPAIR; GENE-EXPRESSION; EGFR MUTATIONS; CISPLATIN; SURVIVAL; CHEMOTHERAPY;

D O I：

10.1158/1078-0432.CCR-11-0790

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose: Excision repair cross-complementation group 1 (ERCC1) is a protein involved in repair of DNA platinum adducts and stalled DNA replication forks. We and others have previously shown the influence of ERCC1 expression upon survival rates and benefit of cisplatin-based chemotherapy in patients with resected non-small-cell lung cancer (NSCLC). However, little is known about the molecular characteristics of ERCC1-positive and ERCC1-negative tumors. Experimental Design: We took advantage of a cohort of 91 patients with resected NSCLC, for which we had matched frozen and paraffin-embedded samples to explore the comparative molecular portraits of ERCC1-positive and ERCC1-negative tumors of NSCLC. We carried out a global molecular analysis including assessment of ERCC1 expression levels by using both immunohistochemistry (IHC) and quantitative reverse transcriptase PCR (qRT-PCR), genomic instability, global gene and miRNA expression, and sequencing of selected key genes involved in lung carcinogenesis. Results: ERCC1 protein and mRNA expression were significantly correlated. However, we observed several cases with clear discrepancies. We noted that ERCC1-negative tumors had a higher rate of genomic abnormalities versus ERCC1-positive tumors. ERCC1-positive tumors seemed to share a common DNA damage response (DDR) phenotype with the overexpression of seven genes linked to DDR. The miRNA expression analysis identified miR-375 as significantly underexpressed in ERCC1-positive tumors. Conclusions: Our data show inconsistencies in ERCC1 expression between IHC and qRT-PCR readouts. Furthermore, ERCC1 status is not linked to specific mutational patterns or frequencies. Finally, ERCC1negative tumors have a high rate of genomic aberrations that could consequently influence prognosis in patients with resected NSCLC. Clin Cancer Res; 17(17); 5562-72. (C)2011 AACR.

引用

页码：5562 / 5572

页数：11

共 46 条

[1] GATA-1 is essential in EGF-mediated induction of nucleotide excision repair activity and ERCC1 expression through ERK2 in human hepatoma cells [J].